Loss of PTEN Expression in Breast Cancer: Association with Clinicopathological Characteristics and Prognosis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 15

PMID 28410191

Citations 66

Authors

Shuting Li

Yanwei Shen

Mengying Wang

Jiao Yang

Meng Lv

Pan Li

Zheling Chen

Jin Yang

Affiliations

Soon will be listed here.

Abstract

Various studies have evaluated the significance of PTEN (phosphatase and tensin homolog deleted from chromosome 10) expression in breast cancer, but their results remain controversial. We conducted a meta-analysis to evaluate the associations of PTEN expression with clinicopathological characteristics and prognosis in breast cancer. PubMed, Embase, Web of Science, and China National Knowledge Infrastructure were searched to identify relevant publications. The associations between PTEN expression and clinicopathological parameters, disease-free survival (DFS), and overall survival (OS) were then assessed via meta-analyses of odds ratio (ORs) and hazard ratio (HRs) with 95% confidence intervals (CIs). Based on 27 studies involving 10,231 patients, the pooled results revealed that PTEN loss was significantly more common in breast cancer than in normal tissues (OR = 12.15, 95% CI = 6.48-22.79, P < 0.00001) and that PTEN loss had clear associations with larger tumor size (> 2 cm, OR = 0.62, 95% CI = 0.48-0.82, P = 0.0006), lymph node metastasis(OR = 0.61, 95% CI = 0.45-0.82, P = 0.0001), later TNM stage(stage III-IV, OR = 0.55, 95% CI = 0.35-0.86, P = 0.009), poor differentiation(OR = 0.37, 95% CI = 0.24-0.59, P < 0.0001), and the highly aggressive triple-negative phenotype (OR = 1.62, 95% CI = 1.23-2.12, P = 0.0005). Moreover, patients with PTEN loss exhibited significantly worse DFS and OS(HR = 1.63, 95% CI = 1.04-2.22, P < 0.00001; HR = 1.41, 95% CI = 1.08-1.73, P < 0.0001; respectively). In conclusion, PTEN loss might predict more aggressive behavior and worse outcomes in patients with breast cancer.

Citing Articles

Post-translational modifications: The potential ways for killing cancer stem cells.

Han X, Qin H, Lu Y, Chen H, Yuan Z, Zhang Y Heliyon. 2024; 10(14):e34015.

PMID: 39092260 PMC: 11292267. DOI: 10.1016/j.heliyon.2024.e34015.

The LCLAT1/LYCAT acyltransferase is required for EGF-mediated phosphatidylinositol-3,4,5-trisphosphate generation and Akt signaling.

Chan V, Camardi C, Zhang K, Orofiamma L, Anderson K, Hoque J Mol Biol Cell. 2024; 35(9):ar118.

PMID: 39024272 PMC: 11449395. DOI: 10.1091/mbc.E23-09-0361.

Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.

Alexander J, Schipper K, Nash S, Brough R, Kemp H, Iacovacci J Br J Cancer. 2024; 130(11):1828-1840.

PMID: 38600325 PMC: 11130209. DOI: 10.1038/s41416-024-02679-7.

Inhibition of MiR-155 Using Exosomal Delivery of Antagomir Can Up-Regulate in Triple Negative Breast Cancer.

Razaviyan J, Sirati-Sabet M, Tafti A, Hadavi R, Karima S, Rajabibazl M Endocr Metab Immune Disord Drug Targets. 2024; 24(14):1664-1676.

PMID: 38424419 DOI: 10.2174/0118715303289859240214103350.

TC2N inhibits distant metastasis and stemness of breast cancer via blocking fatty acid synthesis.

Hao X, Lv Y, Li D, Bai F, Gong J, Pan G J Transl Med. 2024; 22(1):6.

PMID: 38167440 PMC: 10763294. DOI: 10.1186/s12967-023-04721-3.

References

Xu X, Chen S, Chen W, Zheng W, Xia X, Yang H . The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat. 2013; 139(2):329-39. DOI: 10.1007/s10549-013-2563-5. View

Wang J, Guo Y, Wang B, Bi J, Li K, Liang X . Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep. 2012; 39(12):11153-65. DOI: 10.1007/s11033-012-2024-y. View

Krohn A, Diedler T, Burkhardt L, Mayer P, De Silva C, Meyer-Kornblum M . Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012; 181(2):401-12. DOI: 10.1016/j.ajpath.2012.04.026. View

Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S . An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One. 2014; 9(12):e116054. PMC: 4277449. DOI: 10.1371/journal.pone.0116054. View

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Ozden C, B T . Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer. 2015; 15:963. PMC: 4682275. DOI: 10.1186/s12885-015-1770-3. View

Guan X, Wang Y, Xie R, Chen L, Bai J, Lu J . p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med. 2009; 14(4):944-53. PMC: 3823126. DOI: 10.1111/j.1582-4934.2009.00730.x. View

Robledo C, Garcia J, Caballero D, Conde E, Arranz R, Flores T . Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009; 115(16):3728-37. DOI: 10.1002/cncr.24430. View

Lin F, Bacchi C, Baracat E, Carvalho F . Loss of PTEN expression and AKT activation in HER2-positive breast carcinomas. Rev Bras Ginecol Obstet. 2014; 36(8):340-6. View

Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran A . Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 2013; 31(1):801. DOI: 10.1007/s12032-013-0801-7. View

10.

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J . PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res. 2014; 16(1):R13. PMC: 3978618. DOI: 10.1186/bcr3606. View

11.

Jin C, Wang A, Chen J, Liu X, Wang G . Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer. Exp Ther Med. 2012; 4(4):633-639. PMC: 3501400. DOI: 10.3892/etm.2012.651. View

12.

Lazaridis G, Lambaki S, Karayannopoulou G, Eleftheraki A, Papaspirou I, Bobos M . Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther Onkol. 2014; 190(7):636-8, 640-5. DOI: 10.1007/s00066-014-0620-6. View

13.

Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A . Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15(4):356-62. DOI: 10.1038/ng0497-356. View

14.

Capodanno A, Camerini A, Orlandini C, Baldini E, Resta M, Bevilacqua G . Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol. 2009; 40(10):1408-17. DOI: 10.1016/j.humpath.2009.02.005. View

15.

Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X . Clinical and prognostic significance of HIF-1α, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One. 2014; 9(3):e91842. PMC: 3960154. DOI: 10.1371/journal.pone.0091842. View

16.

Majumder P, Sellers W . Akt-regulated pathways in prostate cancer. Oncogene. 2005; 24(50):7465-74. DOI: 10.1038/sj.onc.1209096. View

17.

Knudsen E, Pajak T, Qeenan M, McClendon A, Armon B, Schwartz G . Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst. 2012; 104(23):1825-36. PMC: 3611820. DOI: 10.1093/jnci/djs446. View

18.

Chung M, Jung S, Lee B, Kang M, Lee D . Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int. 2003; 54(1):10-5. DOI: 10.1111/j.1440-1827.2004.01576.x. View

19.

Stern H, Gardner H, Burzykowski T, Elatre W, OBrien C, Lackner M . PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res. 2015; 21(9):2065-74. PMC: 4417419. DOI: 10.1158/1078-0432.CCR-14-2993. View

20.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View